Back to top

ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors

ADC Therapeutics Ltd ($ADCT) announced an update on their ongoing clinical study. The LOTIS-10 study, officially titled “A Phase 1b Open-Label Stud...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ADC Therapeutics SA (ADCT)